Esbriet Slows IPF Progression Regardless of Self-reactive Antibodies

Esbriet Slows IPF Progression Regardless of Self-reactive Antibodies

296465

Esbriet Slows IPF Progression Regardless of Self-reactive Antibodies

Esbriet (pirfenidone) appears to slow the progression of idiopathic pulmonary fibrosis (IPF) regardless of the presence of autoantibodies, which might mean the therapy can work even when IPF is linked to an autoimmune disease, a study suggests. The study, “Effectiveness of pirfenidone in idiopathic pulmonary fibrosis according to the autoantibody status: a retrospective cohort study,” was published in the journal BMC Pulmonary Medicine. In an autoimmune disease, the body’s immune system starts attacking other tissues…

You must be logged in to read/download the full post.